步长制药(603858) - 2018 Q1 - 季度财报

Financial Performance - Net profit attributable to shareholders decreased by 7.26% to CNY 206.24 million year-on-year[6] - Operating revenue increased slightly by 0.09% to CNY 2.43 billion compared to the same period last year[6] - Basic earnings per share decreased by 7.27% to CNY 0.3025[6] - The company's net profit margin for Q1 2018 was not explicitly stated, but the increase in revenue alongside rising costs suggests a need for improved cost management strategies[26] - The net profit for Q1 2018 was CNY 204,756,178.36, a decrease of 7.4% from CNY 220,581,563.46 in Q1 2017[27] - The total comprehensive income for Q1 2018 was CNY 204,827,711.16, compared to CNY 220,584,698.00 in the previous year, indicating a decrease of 7.1%[28] - The total profit for Q1 2018 was CNY 273,400,562.22, down from CNY 287,503,156.09 in Q1 2017, representing a decrease of 4.9%[27] Cash Flow - Net cash flow from operating activities decreased significantly by 69.53% to CNY 140.34 million[6] - The cash inflow from operating activities in Q1 2018 was CNY 3,045,091,424.05, a decrease from CNY 3,517,557,742.01 in the previous year, reflecting a decline of 13.4%[29] - The net cash flow from operating activities for Q1 2018 was -111,191,935.27 RMB, a decrease compared to 68,622,430.38 RMB in the same period last year[33] - The total cash outflow from operating activities was 496,320,778.64 RMB, compared to 588,205,336.54 RMB in the same period last year[33] - Cash received from sales of goods and services was 382,365,185.06 RMB, down from 655,244,934.40 RMB year-over-year[33] Assets and Liabilities - Total assets decreased by 2.97% to CNY 18.63 billion compared to the end of the previous year[6] - Total liabilities decreased to CNY 5,188,985,766.17 from CNY 5,978,005,726.59, reflecting a reduction of approximately 13.2%[20] - The company's total equity increased to CNY 13,438,501,896.90 from CNY 13,218,696,850.09, showing a growth of about 1.66%[20] - Total current assets decreased from ¥7,444,249,334.56 to ¥6,882,970,843.39, indicating a decline in liquidity.[18] Shareholder Information - The total number of shareholders reached 67,173 by the end of the reporting period[10] - The largest shareholder, Bunch (Hong Kong) Holdings Limited, holds 42.61% of the shares, amounting to 290,507,220 shares[10] Government Subsidies and Other Income - The company received government subsidies amounting to CNY 55.79 million related to normal business operations[8] - Other income amounted to ¥55,458,391.94, recognized as government subsidies, which were previously classified under non-operating income.[13] - Cash received from government subsidies related to operating activities increased by 129.50% to ¥101,470,698.83.[14] Operating Costs and Expenses - Total operating costs for Q1 2018 amounted to CNY 2,214,377,110.99, up from CNY 2,162,093,586.48, indicating an increase of approximately 2.0%[26] - Cash paid for various taxes increased by 52.19% to ¥716,141,835.61, reflecting higher value-added tax and corporate income tax payments.[14] - The company reported a significant increase in cash outflow for donations, with operating expenses rising by 515.67% to ¥8,469,137.25.[13] Investment Income - Investment income rose significantly by ¥13,092,263.03, reaching ¥9,564,956.99, due to increased returns from joint ventures and associates.[13] - The company reported an investment income of CNY 9,955,010.85 in Q1 2018, compared to a loss of CNY 3,527,306.04 in the same period last year[27] Other Financial Metrics - The weighted average return on equity decreased by 0.19 percentage points to 1.56%[6] - Accounts payable increased by 96.15% to ¥5,100,000 due to the rise in bank acceptance bills from subsidiary Liaoning Aoda Pharmaceutical Co., Ltd.[12] - Prepayments decreased by 57.43% to ¥130,132,087, primarily due to a reduction in advance payments from Shaanxi Buchang Pharmaceutical Co., Ltd.[12] - Tax payable decreased by 55.71% to ¥207,773,184, mainly due to the payment of value-added tax and corporate income tax during the reporting period.[12] - Other comprehensive income increased by 34.66% to ¥277,939.11, influenced by foreign currency translation differences.[12]